Table 3.

Univariate log-rank analysis for important clinicopathological variables and CLCA1 expression

Parameter		No. of case	DSS		LRFS		MeFS
			No. of event	p-value	No. of event	p-value	No. of event	p-value
Gender	Male	108 (62.8%)	20 (18.5%)	0.6027	15 (13.9%)	0.3096	14 (13.0%)	0.1047
	Female	64 (37.2%)	11 (17.2%)		7 (10.9%)		15 (23.4%)
Age	<70	106 (61.6%)	19 (17.9%)	0.7158	14 (13.2%)	0.9630	18 (17.0%)	0.9520
	≧70	66 (38.4%)	12 (18.2%)		8 (12.1%)		11 (16.7%)
Pre-Tx tumor status (Pre-T)	T1-T2	81 (47.1%)	10 (12.3%)	0.0484*	7 (8.6%)	0.0836	10 (12.3%)	0.1288
	T3-T4	91 (52.9%)	21 (23%)		15 (16.5%)		19 (20.9%)
Pre-Tx nodal status (Pre-N)	N0	125 (72.7%)	19 (15.2%)	0.0059*	12 (9.6%)	0.0025*	18 (14.4%)	0.0866
	N1-N2	47 (27.3%)	21 (44.7%)		10 (21.3%)		11 (23.4%)
Post-Tx tumor status (Post-T)	T1-T2	86 (50%)	7 (8.1%)	0.0014*	5 (5.8%)	0.0056*	8 (9.3%)	0.0123*
	T3-T4	86 (50%)	24 (27.9%)		17 (19.8%)		21 (24.4%)
Post-Tx nodal status (Post-N)	N0	123 (71.5%)	21 (17%)	0.4654	15 (12.2%)	0.6267	20 (16.3%)	0.8403
	N1-N2	49 (28.5%)	10 (20.4%)		7 (14.3%)		9 (18.4%)
Vascular invasion	Absent	157 (91.3%)	25 (15.9%)	0.0123*	17 (10.8%)	0.0023*	26 (16.6%)	0.7236
	Present	15 (8.7%)	6 (40%)		5 (33.3%)		3 (20%)
Perineurial invasion	Absent	167 (97.1%)	29 (17.4%)	0.0994	20 (12.0%)	0.0083*	28 (16.8%)	0.8157
	Present	5 (2.9%)	2 (40%)		2 (40%)		1 (20%)
Tumor regression grade	Grade 0-1	37 (21.5%)	13 (35.1%)	0.0037*	10 (27.0%)	0.0021*	14 (37.8%)	0.0008*
	Grade 2~3	118 (68.6%)	17 (14.4%)		12 (10.2%)		14 (11.9%)
	Grade 4	17 (9.9%)	1 (5.9%)		0 (0%)		1 (5.9%)
CLCA1 expression	Low Exp.	103 (59.9%)	12 (11.7%)	0.0041*	9 (8.7%)	0.0012*	12 (11.7%)	0.0114*
	High Exp.	69 (40.1%)	19 (27.5%)		18 (26.1%)		19 (27.5%)

DSS, disease-specific survival; LRFS, local recurrence-free survival; MeFS, metastasis-free survival; *, statistically significant